[1] |
SI Y H, WANG C Y, GUO Y,et al. Prevalence of osteoporosis in patients with type 2 diabetes mellitus in the Chinese mainland:a systematic review and meta-analysis[J]. Iran J Public Health,2019,48(7):1203-1214.
|
[2] |
MCCRACKEN E, MONAGHAN M, SREENIVASAN S. Pathophysiology of the metabolic syndrome[J]. Clin Dermatol,2018,36(1):14-20. DOI:10.1016/j.clindermatol.2017.09.004.
|
[3] |
HOU X H, LU J M, WENG J P,et al. Impact of waist circumference and body mass index on risk of cardiometabolic disorder and cardiovascular disease in Chinese adults:a national diabetes and metabolic disorders survey[J]. PLoS One,2013,8(3):e57319. DOI:10.1371/journal.pone.0057319.
|
[4] |
毛维维,张织茵,盛辉. 2型糖尿病绝经后患者腰椎体积骨密度与内脏脂肪/皮下脂肪组织比率的相关性分析[J]. 同济大学学报:医学版,2019,40(3):356-360. DOI:10.16118/j.1008-0392.2019.03.017.
|
[5] |
ROMERE C, DUERRSCHMID C, BOURNAT J,et al. Asprosin,a fasting-induced glucogenic protein hormone[J]. Cell,2016,165(3):566-579. DOI:10.1016/j.cell.2016.02.063.
|
[6] |
SONMEZ K, ZAVERI N T, KERMAN I A,et al. Evolutionary sequence modeling for discovery of peptide hormones[J]. PLoS Comput Biol,2009,5(1):e1000258. DOI:10.1371/journal.pcbi.1000258.
|
[7] |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中国实用内科杂志,2018,38(4):292-344. DOI:10.19538/j.nk2018040108.
|
[8] |
PEDRAZZANI C, CONTI C, ZAMBONI G A,et al. Impact of visceral obesity and sarcobesity on surgical outcomes and recovery after laparoscopic resection for colorectal cancer[J]. Clin Nutr,2020,39(12):3763-3770. DOI:10.1016/j.clnu.2020.04.004.
|
[9] |
高岩,于艳梅,高志辉,等. 2型糖尿病患者合并慢性肾脏疾病其肾脏功能与胰岛素抵抗的相关性研究[J]. 医学理论与实践,2020,33(12):1908-1910,1913. DOI:10.19381/j.issn.1001-7585.2020.12.006.
|
[10] |
王秀景,胡天晓,阮芸,等. 新诊断2型糖尿病患者血清鸢尾素水平与腹腔内脏脂肪面积关系的研究[J]. 中国糖尿病杂志,2021,29(7):488-491. DOI:10.3969/j.issn.1006-6187.2021.07.002.
|
[11] |
王慧卿,王桂英,王迎宾,等. 2型糖尿病并内脏型肥胖患者内脏脂肪面积的分析[J]. 中华肥胖与代谢病电子杂志,2019,5(3):148-152. DOI:10.3877/cma.j.issn.2095-9605.2019.03.005.
|
[12] |
KACHUR S, LAVIE C J, DE SCHUTTER A,et al. Obesity and cardiovascular diseases[J]. Minerva Med,2017,108(3):212-228. DOI:10.23736/s0026-4806.17.05022-4.
|
[13] |
顾丽萍,申婷婷,马宇航,等. 新诊断2型糖尿病患者血清spexin水平与内脏脂肪面积及代谢指标的相关性分析[J]. 同济大学学报:医学版,2020,41(2):172-177. DOI:10.16118/j.1008-0392.2020.02.006.
|
[14] |
LONG W J, XIE X M, DU C Q,et al. Decreased circulating levels of asprosin in obese children[J]. Horm Res Paediatr,2019,91(4):271-277. DOI:10.1159/000500523.
|
[15] |
GU L P, DING X Y, WANG Y F,et al. Spexin alleviates insulin resistance and inhibits hepatic gluconeogenesis via the FoxO1/PGC-1α pathway in high-fat-diet-induced rats and insulin resistant cells[J]. Int J Biol Sci,2019,15(13):2815-2829. DOI:10.7150/ijbs.31781.
|
[16] |
ZHANG L, CHEN C, ZHOU N,et al. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride[J]. Clin Chim Acta,2019,489:183-188. DOI:10.1016/j.cca.2017.10.034.
|
[17] |
LI X, LIAO M, SHEN R,et al. Plasma asprosin levels are associated with glucose metabolism,lipid,and sex hormone profiles in females with metabolic-related diseases[J]. Mediators Inflamm,2018,2018:7375294. DOI:10.1155/2018/7375294.
|
[18] |
DUERRSCHMID C, HE Y, WANG C,et al. Asprosin is a centrally acting orexigenic hormone[J]. Nat Med,2017,23(12):1444-1453. DOI:10.1038/nm.4432.
|
[19] |
GU L P, MA Y H, GU M Y,et al. Spexin peptide is expressed in human endocrine and epithelial tissues and reduced after glucose load in type 2 diabetes[J]. Peptides,2015,71:232-239. DOI:10.1016/j.peptides.2015.07.018.
|
[20] |
GE J F, WALEWSKI J L, ANGLADE D,et al. Regulation of hepatocellular fatty acid uptake in mouse models of fatty liver disease with and without functional leptin signaling:roles of NfKB and SREBP-1C and the effects of spexin[J]. Semin Liver Dis,2016,36(4):360-372. DOI:10.1055/s-0036-1597248.
|
[21] |
JUNG T W, KIM H C, KIM H U,et al. Asprosin attenuates insulin signaling pathway through PKCδ-activated ER stress and inflammation in skeletal muscle[J]. J Cell Physiol,2019,234(11):20888-20899.DOI:10.1002/jcp.28694.
|